Pharmasset Initiates First Time In Human Study Of PSI-938 For The Treatment Of Hepatitis C

Links shared publicly online about this topic.

  • 1,253
    total visits

Pharmasset Initiates First Time In Human Study Of PSI-938 For The Treatment Of Hepatitis C

medicalnewstoday.com —

Pharmasset, Inc. (Nasdaq: VRUS) announced that dosing has initiated in a phase 1, single ascending dose (SAD) study in healthy volunteers with PSI-938, a third generation purine nucleotide analog

View full resource at medicalnewstoday.com

Tags: Liver Condition, Hepatitis, Hepatitis C, Pharma

  • Share

Most Recently Shared on April 9, 2010 at 9:07 pm By:

mnt_clinical MNT Clinical Trials

Pharmasset Initiates First Time In Human Study Of PSI-938 For The Treatment Of Hepatitis C http://mnt.to/3B2n #clinicaltrials

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Pharma News MNT Pharma News

MNT Drug Approvals MNT Drug Approvals

Advertisement